You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 158 No. 18, October 12, 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (82)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Tobacco
 •Alert me on articles by topic

A Randomized Trial of Nortriptyline for Smoking Cessation

Allan V. Prochazka, MD, MSc; Michael J. Weaver, MD, MHS; Richard T. Keller, BSN, MN; G. Edward Fryer, PhD; Patricia A. Licari, MSHA; Donna Lofaso, BSN

Arch Intern Med. 1998;158:2035-2039.

Background  Smoking cessation rates with current therapy are suboptimal. One class of drugs that may improve cessation is the tricyclics.

Objective  To add nortriptyline hydrochloride to a behavioral smoking cessation program to enhance cessation rates and reduce withdrawal symptoms.

Subjects and Methods  We conducted a randomized, double-blind, placebo-controlled trial at an affiliated Department of Veterans Affairs Medical Center and an Army Medical Center. Subjects were aged 18 through 70 years, smoked 10 or more cigarettes per day, and were without current major depression. Nortriptyline hydrochloride or matched placebo was started at 25 mg before bed 10 days prior to quit day and titrated to 75 mg/d or to the maximal tolerated dose. The behavioral intervention consisted of 2 group sessions and 12 individual follow-up visits. Withdrawal symptoms were measured using a daily diary, and smoking cessation was defined as self-reported abstinence, expired carbon monoxide of 9 ppm or less, and a 6-month urine cotinine level of less than 50 ng/mL.

Results  A total of 214 patients were randomized (108 to nortriptyline and 106 to placebo). There was a significant reduction in several withdrawal symptoms including anxious/tense, anger/irritability, difficulty concentrating, restlessness, and impatience by day 8 after quit day in the nortriptyline group. The cessation rate at 6 months was 15 (14%) of 108 and 3 (3%) of 106, respectively (P=.003; absolute difference, 11%; 95% confidence interval, -18% to -4%). Nortriptyline caused frequent adverse effects, including dry mouth (64%) and dysgeusia (20%).

Conclusions  We conclude that nortriptyline led to an increased short-term cessation rate compared with placebo. In addition, there were significant, but relatively small, reductions in withdrawal symptoms. Nortriptyline may represent a new therapeutic approach to smoking cessation.


From the Ambulatory Care, Denver Veterans Affairs Medical Center, Denver, Colo (Dr Prochazka and Mss Licari and Lofaso); the Division of General Internal Medicine (Dr Prochazka and Ms Licari) and the Department of Family Medicine (Dr Fryer), University of Colorado Health Sciences Center, Denver; Fitzsimons Army Medical Center, Aurora, Colo (Dr Weaver and Mr Keller); Inteck Incorporated, Denver (Dr Weaver); and the 528th Medical Detachment, United States Army, Fort Bragg, NC (Mr Keller).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Stroke prevention: modifying risk factors
Romero et al.
Therapeutic Advances in Cardiovascular Disease 2008;2:287-303.
ABSTRACT  

Efficacy of Bupropion and Nortriptyline for Smoking Cessation Among People at Risk for or With Chronic Obstructive Pulmonary Disease
Wagena et al.
Arch Intern Med 2005;165:2286-2292.
ABSTRACT | FULL TEXT  

Pharmacotherapy for Nicotine Dependence
Henningfield et al.
CA Cancer J Clin 2005;55:281-299.
ABSTRACT | FULL TEXT  

A Randomized Trial of Nortriptyline Combined With Transdermal Nicotine for Smoking Cessation
Prochazka et al.
Arch Intern Med 2004;164:2229-2233.
ABSTRACT | FULL TEXT  

Extended Nortriptyline and Psychological Treatment for Cigarette Smoking
Hall et al.
Am. J. Psychiatry 2004;161:2100-2107.
ABSTRACT | FULL TEXT  

Psychological Intervention and Antidepressant Treatment in Smoking Cessation
Hall et al.
Arch Gen Psychiatry 2002;59:930-936.
ABSTRACT | FULL TEXT  

Stopping Smoking* : A Prospective, Randomized, Double-Blind Study Comparing Nortriptyline to Placebo
da Costa et al.
Chest 2002;122:403-408.
ABSTRACT | FULL TEXT  

Treatment of Tobacco Use and Dependence
Rigotti
NEJM 2002;346:506-512.
FULL TEXT  

Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression
WAGENA et al.
Thorax 2001;56:587a-588.
FULL TEXT  

Depressive Symptoms and Cigarette Smoking Among Teens
Goodman and Capitman
Pediatrics 2000;106:748-755.
ABSTRACT | FULL TEXT  

A 36-Year-Old Woman Who Smokes Cigarettes
Rigotti
JAMA 2000;284:741-749.
FULL TEXT  

Antidepressants and Smoking Cessation
Gambassi et al.
Arch Intern Med 1999;159:1257-1258.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.